CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Lenalidomide +1 moredrug
Likely dose
Recombinant human erythropoietin 40,000 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00910858
NCT00910858Phase 2Completed
CompareCT.gov

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

Celgene Corporation·interventional·Posted Jun 1, 2009·Updated Sep 30, 2013

In Brief

A Phase 2 clinical trial evaluating Lenalidomide and Recombinant human erythropoietin for Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS). Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to assess pharmacokinetic and pharmacodynamic characteristics of oral lenalidomide monotherapy administered to patients with Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLow- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 1, 2009
Enrollment StartJan 1, 2005
Primary CompletionApr 1, 2006
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.1 years ago

Interventions

Lenalidomidedrug

Lenalidomide 5-mg capsules for oral administration

Recombinant human erythropoietindrug

Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.